{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-201709","form_type":"8-K","ticker":"STAA","cik":"0000718937","company_name":"STAAR SURGICAL CO","filed_at":"2023-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.488918+00:00","generated_at":"2026-06-12T15:28:25.844366+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"STAAR Surgical Q2 ICL sales record $93.1M; GAAP EPS $0.12; guides FY ICL sales $320M-$325M","bullets":["Record ICL sales of $93.1M, +19% YoY; ICL units +21% YoY.","Net sales $92.3M (+14% YoY); GAAP EPS $0.12 vs $0.26 prior year; adjusted ICL EPS $0.19.","Updated FY2023 ICL sales outlook to $320M-$325M (midpoint ~20% growth).","APAC ICL sales grew 26% YoY; U.S. ICL sales +10% vs industry -15%.","Gross margin 76.6% vs 78.8% prior year; cash & investments $209.5M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-201709","json":"https://secwatch.observer/filing/0001193125-23-201709.json","markdown":"https://secwatch.observer/filing/0001193125-23-201709.md","text":"https://secwatch.observer/filing/0001193125-23-201709.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/718937/000119312523201709/0001193125-23-201709-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/718937/000119312523201709/d495417d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T15:28:25.844366+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a6fce35768bc861fba14ff35d97bc6fb0aef096f","claim":"STAAR SURGICAL CO reported the second quarter ended June 30, 2023 results: revenue $92.3 million, net income $6.1 million or $0.12 per diluted share, EPS $0.12 per diluted share. Guidance lowered.","evidence_excerpt":"and marketer of implantable lenses for the eye, today reported financial results for the second quarter ended June 30, 2023. Second Quarter 2023 Overview • Net Sales of $92.3 Million Up 14% includes a $0.7 Million sales reduction related to Other Products • Record ICL Sales of $93.1 Million Up 19% Y/Y and Up 20% Y/Y in Constant Currency • ICL Units Up 21% Y/Y","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/718937/000119312523201709/0001193125-23-201709-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Revenue","value":"$92.3 million"},{"label":"Net income","value":"$6.1 million or $0.12 per diluted share"},{"label":"EPS","value":"$0.12 per diluted share"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}